NO20043634L - Mono-ester- og asymmetrisk substituerede di-ester-prodrugs av dopamin D1 reseptoragonister - Google Patents
Mono-ester- og asymmetrisk substituerede di-ester-prodrugs av dopamin D1 reseptoragonisterInfo
- Publication number
- NO20043634L NO20043634L NO20043634A NO20043634A NO20043634L NO 20043634 L NO20043634 L NO 20043634L NO 20043634 A NO20043634 A NO 20043634A NO 20043634 A NO20043634 A NO 20043634A NO 20043634 L NO20043634 L NO 20043634L
- Authority
- NO
- Norway
- Prior art keywords
- ester
- mono
- dopamine
- asymmetrically substituted
- receptor agonists
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D221/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
- C07D221/02—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
- C07D221/04—Ortho- or peri-condensed ring systems
- C07D221/18—Ring systems of four or more rings
Landscapes
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicinal Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Psychiatry (AREA)
- Addiction (AREA)
- Psychology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Hospice & Palliative Care (AREA)
- Pain & Pain Management (AREA)
- Urology & Nephrology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Other In-Based Heterocyclic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
SE0200478A SE0200478D0 (sv) | 2002-02-15 | 2002-02-15 | Mono-ester and asymmetrically substituted di-ester pro-drugs of the dopamine D1 receptor agonist A-86929 |
SE0200474A SE0200474D0 (sv) | 2002-02-17 | 2002-02-17 | Mono-ester and asymmetrically substituted di-ester pro-drugs of the dopamine D1 receptor agonists Dihydrexidine and Dinapsoline |
PCT/US2003/004592 WO2003070245A1 (en) | 2002-02-15 | 2003-02-14 | Mono-ester and asymmetrically substituted di-ester pro-drugs of the dopamine d1 receptor agonists |
Publications (1)
Publication Number | Publication Date |
---|---|
NO20043634L true NO20043634L (no) | 2004-11-11 |
Family
ID=27759833
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NO20043634A NO20043634L (no) | 2002-02-15 | 2004-08-31 | Mono-ester- og asymmetrisk substituerede di-ester-prodrugs av dopamin D1 reseptoragonister |
Country Status (11)
Country | Link |
---|---|
US (1) | US7220754B2 (da) |
EP (1) | EP1480647B1 (da) |
JP (1) | JP2005526728A (da) |
AT (1) | ATE406896T1 (da) |
AU (1) | AU2003217430B2 (da) |
CA (1) | CA2476115A1 (da) |
DE (1) | DE60323339D1 (da) |
DK (1) | DK1480647T3 (da) |
ES (1) | ES2314189T3 (da) |
NO (1) | NO20043634L (da) |
WO (1) | WO2003070245A1 (da) |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9046537B2 (en) | 2003-09-22 | 2015-06-02 | Enzo Biochem, Inc. | Method for treating inflammation by administering a compound which binds LDL-receptor-related protein (LRP) ligand binding domain |
EP1699450A4 (en) * | 2003-12-23 | 2009-11-11 | Darpharma Inc | Simultaneous administration of dopamine receptor bindings |
US9052324B2 (en) | 2004-05-19 | 2015-06-09 | Enzo Biochem, Inc. | Compounds and assays for controlling Wnt activity |
US8596306B2 (en) * | 2005-10-27 | 2013-12-03 | Synthetic Gas Solutions, Llc | Perfluorocarbon gas insufflation |
AU2007216994A1 (en) * | 2006-02-21 | 2007-08-30 | Purdue Research Foundation | Trans-fused chromenoisoquinolines, synthesis and methods for use |
JP5734957B2 (ja) | 2009-04-21 | 2015-06-17 | パーデュー・リサーチ・ファウンデーションPurdue Research Foundation | ドーパミンレセプターのオクタヒドロベンゾイソキノリンモジュレーター及びその使用 |
US20150291625A1 (en) * | 2012-11-08 | 2015-10-15 | Pfizer Inc. | Heteroaromatic Compounds and their Use as Dopamine D1 Ligands |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4282227A (en) | 1980-05-22 | 1981-08-04 | Smithkline Corporation | Renal vasodilating 3,4-dihydroxyphenyltetrahydrothienopyridines |
US4340600A (en) | 1980-05-22 | 1982-07-20 | Smithkline Corporation | Renal dilating methods and compositions using 4-(3,4-dihydroxyphenyl)-1,2,3,4-tetrahydroisoquinolines |
JPH02138A (ja) * | 1987-09-18 | 1990-01-05 | Banyu Pharmaceut Co Ltd | L‐ドーパ誘導体 |
US5047536A (en) * | 1989-03-17 | 1991-09-10 | Purdue Research Foundation | Hexahydrobenzo(A)phenanthridine compounds |
IE912999A1 (en) | 1990-09-07 | 1992-03-11 | Abbott Lab | Phenanthridine compounds |
JP3476193B2 (ja) * | 1992-05-26 | 2003-12-10 | パーデュー・リサーチ・ファウンデーション | 置換ヘキサヒドロベンゾ〔α〕フェナンスリジン類 |
JP2710695B2 (ja) | 1993-04-06 | 1998-02-10 | アボツト・ラボラトリーズ | ドーパミンアゴニストとしての四環式化合物 |
AU2966795A (en) * | 1994-07-15 | 1996-02-16 | Purdue Research Foundation | Optically active isomers of dihydrexidine and its substituted analogs |
ATE209915T1 (de) | 1995-08-18 | 2001-12-15 | Purdue Research Foundation | Neue kondensierten isochinoline als dopamin- rezeptor-liganden |
-
2003
- 2003-02-14 DK DK03713475T patent/DK1480647T3/da active
- 2003-02-14 DE DE60323339T patent/DE60323339D1/de not_active Expired - Fee Related
- 2003-02-14 AT AT03713475T patent/ATE406896T1/de not_active IP Right Cessation
- 2003-02-14 WO PCT/US2003/004592 patent/WO2003070245A1/en active Application Filing
- 2003-02-14 US US10/503,796 patent/US7220754B2/en not_active Expired - Fee Related
- 2003-02-14 CA CA002476115A patent/CA2476115A1/en not_active Abandoned
- 2003-02-14 JP JP2003569201A patent/JP2005526728A/ja active Pending
- 2003-02-14 ES ES03713475T patent/ES2314189T3/es not_active Expired - Lifetime
- 2003-02-14 EP EP03713475A patent/EP1480647B1/en not_active Expired - Lifetime
- 2003-02-14 AU AU2003217430A patent/AU2003217430B2/en not_active Ceased
-
2004
- 2004-08-31 NO NO20043634A patent/NO20043634L/no unknown
Also Published As
Publication number | Publication date |
---|---|
JP2005526728A (ja) | 2005-09-08 |
EP1480647A1 (en) | 2004-12-01 |
WO2003070245B1 (en) | 2004-05-27 |
AU2003217430A1 (en) | 2003-09-09 |
EP1480647A4 (en) | 2005-07-13 |
EP1480647B1 (en) | 2008-09-03 |
DE60323339D1 (de) | 2008-10-16 |
DK1480647T3 (da) | 2009-01-26 |
WO2003070245A1 (en) | 2003-08-28 |
ATE406896T1 (de) | 2008-09-15 |
CA2476115A1 (en) | 2003-08-28 |
AU2003217430B2 (en) | 2008-10-23 |
US7220754B2 (en) | 2007-05-22 |
US20050096469A1 (en) | 2005-05-05 |
ES2314189T3 (es) | 2009-03-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CY1112941T1 (el) | Δικυκλικοι αναστολεις της μεκ | |
NZ514409A (en) | C7 ester substituted taxanes as antitumor agents | |
CR9587A (es) | Derivados de piridazina | |
NO20062098L (no) | Faststofftilstandmontelukast | |
MX2007004699A (es) | Derivados de indol y bencimidazol. | |
BR9904162A (pt) | 4-carboxiamino-2-metil-1,2,3,4-tetra-hidroquinolinas aneladas | |
SE0201635D0 (sv) | Novel compounds | |
IL204594A (en) | Protein kinase inhibitors | |
BRPI0506477A (pt) | compostos farmaceuticamente úteis e inovadores | |
AR021482A1 (es) | Compuestos de 4-carboxiamino-1,2,3,4-tetrahidroquinolinas, composiciones farmaceuticas, kit, y uso de los mismos. | |
CA2757418C (en) | Pharmaceutical formulations comprising nitrocatechol derivatives and methods of making the same | |
BG105428A (en) | 4-carboxyamino-2-substituted-1,2,3,4-tetrahydroquinolines as cetp inhibitors | |
GEP20084572B (en) | Novel quinoline derivatives | |
NO20050016L (no) | Difenylazetidinonderivater for behandling av forstyrrelser i lipid metabolismen | |
ECSP014097A (es) | Derivados de tiofeno utiles como agentes anticancerosos | |
ECSP088229A (es) | Derivados de pirazolona como inhibidores de 11-beta hsd1 | |
RS50670B (sr) | Supstitucionisani derivati hinolina kao mitotički kinezinski inhibitori | |
CY1110034T1 (el) | Παραγωγα 1,2,4,5-τετραϋδρο-3h-βενζαζεπινων, μεθοδος παρασκευης αυτων και οι φαρμακευτικες συνθεσεις που τα περιεχουν | |
IN266803B (da) | ||
BRPI0409105A (pt) | análogos de quinobenzoxazina substituìdos | |
NO20043634L (no) | Mono-ester- og asymmetrisk substituerede di-ester-prodrugs av dopamin D1 reseptoragonister | |
DE60002733D1 (de) | Diester prodrugs von decahydroischinoline-3-carbonsäure | |
ATE371644T1 (de) | Neues alkaloidderivat und dieses enthaltende pharmazeutische zusammensetzung | |
WO2004091627A3 (en) | Heterocyclic substituted 1,4-dihydro-4-oxo-1,8-naphthpyridine analogs | |
TW200724168A (en) | Pharmaceutical compositions |